You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

RIVASTIGMINE TARTRATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Rivastigmine Tartrate, and what generic alternatives are available?

Rivastigmine Tartrate is a drug marketed by Alembic Pharms Ltd, Apotex Inc, Aurobindo Pharma, Cadila Pharms Ltd, Chartwell Rx, Dr Reddys Labs Inc, Macleods Pharms Ltd, Orbion Pharms, Sun Pharm, and Watson Labs. and is included in ten NDAs.

The generic ingredient in RIVASTIGMINE TARTRATE is rivastigmine tartrate. There are thirty-two drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the rivastigmine tartrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Rivastigmine Tartrate

A generic version of RIVASTIGMINE TARTRATE was approved as rivastigmine tartrate by SUN PHARM on October 22nd, 2007.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for RIVASTIGMINE TARTRATE?
  • What are the global sales for RIVASTIGMINE TARTRATE?
  • What is Average Wholesale Price for RIVASTIGMINE TARTRATE?
Drug patent expirations by year for RIVASTIGMINE TARTRATE
Drug Prices for RIVASTIGMINE TARTRATE

See drug prices for RIVASTIGMINE TARTRATE

Recent Clinical Trials for RIVASTIGMINE TARTRATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Duke UniversityPhase 1/Phase 2
Taishoff Family FoundationPhase 1/Phase 2
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Phase 1/Phase 2

See all RIVASTIGMINE TARTRATE clinical trials

Pharmacology for RIVASTIGMINE TARTRATE
Anatomical Therapeutic Chemical (ATC) Classes for RIVASTIGMINE TARTRATE
Paragraph IV (Patent) Challenges for RIVASTIGMINE TARTRATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
EXELON Oral Solution rivastigmine tartrate 2 mg/mL 021025 1 2004-11-05
EXELON Capsules rivastigmine tartrate 1.5 mg, 3 mg, 4.5 mg and 6 mg 020823 3 2004-04-21

US Patents and Regulatory Information for RIVASTIGMINE TARTRATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Orbion Pharms RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 090879-004 Jun 10, 2015 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Macleods Pharms Ltd RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 203148-004 Aug 22, 2014 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sun Pharm RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 077131-001 Oct 22, 2007 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Orbion Pharms RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 090879-001 Jun 10, 2015 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Alembic Pharms Ltd RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 091689-001 Jun 12, 2012 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chartwell Rx RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 207797-002 Sep 28, 2017 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Dr Reddys Labs Inc RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 077130-004 Oct 31, 2007 AB RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.